ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years
Shuai Wu
Matched on ORCID iD 0000-0001-6122-6853; OpenAlex author ID A5100740520. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 3 papers
Papers 5
- Endoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fat-lesion strain ratio, and mean strain h… Co-author DOI 10.1007/s10238-025-01969-5↗
- Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. Last author DOI 10.1186/s10020-025-01180-y↗
- Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
- Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. First author DOI 10.1002/cam4.7229↗
- RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zheng Wu · 4 shared papers, 2022–2025 · strength 0.82
- Paper Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. DOI 10.1186/s10020-025-01180-y↗
- Paper Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. DOI 10.1186/s13062-025-00595-1↗
- Paper Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy… DOI 10.1002/cam4.7229↗
- Weikun Qian · 3 shared papers, 2022–2025 · strength 0.58
- Paper Endoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fa… DOI 10.1007/s10238-025-01969-5↗
- Paper Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. DOI 10.1186/s13062-025-00595-1↗
- Paper RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcino… DOI 10.7150/ijbs.72204↗
- Jiaqiang Ren · 2 shared papers, 2024–2025 · strength 0.46
- Paper Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. DOI 10.1186/s10020-025-01180-y↗
- Paper Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy… DOI 10.1002/cam4.7229↗
- Liang Han · 2 shared papers, 2024–2025 · strength 0.46
- Paper Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. DOI 10.1186/s10020-025-01180-y↗
- Paper Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy… DOI 10.1002/cam4.7229↗
- Jie Hao · 2 shared papers, 2025 · strength 0.44
- Cancan Zhou · 2 shared papers, 2025 · strength 0.44
- Zeen Zhu · 2 shared papers, 2022–2025 · strength 0.35
- Qingyong Ma · 2 shared papers, 2022–2025 · strength 0.35
- Wunai Zhang · 2 shared papers, 2022–2025 · strength 0.35
- Jiantao Mo · 1 shared paper, 2025 · strength 0.25
- Hao Sun · 1 shared paper, 2025 · strength 0.22
- Fangzhou Wang · 1 shared paper, 2025 · strength 0.22
- Zheng Wang · 1 shared paper, 2025 · strength 0.22
- Zheng Wu · 1 shared paper, 2025 · strength 0.22
- Ruiqi Cao · 1 shared paper, 2025 · strength 0.22
- Xuqi Li · 1 shared paper, 2025 · strength 0.22
- Jie Li · 1 shared paper, 2024 · strength 0.22
- Simei Zhang · 1 shared paper, 2022 · strength 0.14
- Zheng Wang · 1 shared paper, 2022 · strength 0.14
- Weifan Zhang · 1 shared paper, 2022 · strength 0.14
- Li Li · 1 shared paper, 2022 · strength 0.14
- Yangyang Yue · 1 shared paper, 2022 · strength 0.14
- Keping Xie · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.